Standard BioTools Inc’s recent filing unveils that its Director Casdin Partners Master Fund, L acquired Company’s shares for reported $0.26 million on May 23 ’24. In the deal valued at $2.60 per share,100,000 shares were bought. As a result of this transaction, Casdin Partners Master Fund, L now holds 46,075,821 shares worth roughly $106.9 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Casdin Partners Master Fund, L bought 150,000 shares, generating $387,735 in total proceeds. Upon buying the shares at $2.58, the Director now owns 45,975,821 shares.
Before that, Casdin Partners Master Fund, L bought 350,000 shares. Standard BioTools Inc shares valued at $895,930 were divested by the Director at a price of $2.56 per share. As a result of the transaction, Casdin Partners Master Fund, L now holds 45,825,821 shares, worth roughly $106.32 million.
TD Cowen initiated its Standard BioTools Inc [LAB] rating to a Buy in a research note published on April 16, 2024; the price target was $3.50. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early April with a ‘”a Buy”‘ rating. KeyBanc Capital Markets began covering LAB with “an Overweight” recommendation on July 12, 2023.
Price Performance Review of LAB
On Friday, Standard BioTools Inc [NASDAQ:LAB] saw its stock fall -7.94% to $2.32. Over the last five days, the stock has lost -6.45%. Standard BioTools Inc shares have risen nearly 4.98% since the year began. Nevertheless, the stocks have risen 1.75% over the past one year. While a 52-week high of $3.16 was reached on 04/09/24, a 52-week low of $1.57 was recorded on 01/05/24. SMA at 50 days reached $2.57, while 200 days put it at $2.42. A total of 2.33 million shares were traded, compared to the trading of 1.09 million shares in the previous session.
Levels Of Support And Resistance For LAB Stock
The 24-hour chart illustrates a support level at 2.25, which if violated will result in even more drops to 2.18. On the upside, there is a resistance level at 2.44. A further resistance level may holdings at 2.57. The Relative Strength Index (RSI) on the 14-day chart is 36.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.07, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.55%. Stochastics %K at 25.88% indicates the stock is a holding.
